Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.62 |
| ▸ | HTR2B | P41595 | 7/20 | 0.57 |
| ▸ | HTR2C | P28335 | 6/20 | 0.57 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22704945 | 0.90 | ADORA3 (0.81) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL26534074 | 0.81 | ADORA3 (0.67) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL22704946 | 0.80 | ADORA3 (0.66) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL19459458 | 0.78 | ADORA3 (0.77) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL19464937 | 0.78 | ADORA3 (0.77) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL19464938 | 0.78 | ADORA3 (0.77) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL2363334 | 0.78 | ADORA3 (1.00) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL5816714 | 0.78 | ADORA3 (0.82) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL21710876 | 0.78 | ADORA3 (1.00) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B | |
| SCHEMBL22933437 | 0.78 | ADORA3 (0.77) | ADORA3HSP90AA1HSP90B1ADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | ADORA3 378/4885HSP90AA1 2538/4885HSP90B1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.